

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

hTERT-HPNE

RRID:CVCL_C466

Type: Cell Line

Proper Citation

ATCC Cat# CRL-4023, RRID:CVCL_C466

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C466

Proper Citation: ATCC Cat# CRL-4023, RRID:CVCL_C466

Description: Cell line hTERT-HPNE is a Telomerase immortalized cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:12589817](#), [PMID:17332339](#)

Category: Telomerase immortalized cell line

Organism: Homo sapiens (Human)

Name: hTERT-HPNE

Synonyms: hTERT-Human Pancreatic Nestin-Expressing cells

Cross References: BTO:BTO_0006092, EFO:EFO_0022415, ATCC:CRL-4023, BioSample:SAMN05292450, Wikidata:Q54896625

ID: CVCL_C466

Vendor: ATCC

Catalog Number: CRL-4023

Record Creation Time: 20250130T071931+0000

Record Last Update: 20260905T184041+0000

Ratings and Alerts

No rating or validation information has been found for hTERT-HPNE.

No alerts have been found for hTERT-HPNE.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 57 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Poimenidou M, et al. (2026) Mitochondria-targeted metformin analogs activate the ER stress-unfolded protein response pathway to drive apoptosis in pancreatic cancer. *Cell death & disease*, 17(1).

Pan Z, et al. (2026) OCIAD2-IQGAP1 interaction promotes pancreatic cancer progression by suppressing oxidative stress and mitochondria-mediated apoptosis. *Cellular signalling*, 138, 112217.

Zhang H, et al. (2026) Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer. *Cancer & metabolism*, 14(1).

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. *Genome research*, 36(2), 275.

Shi X, et al. (2026) Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e20029.

Qin G, et al. (2026) HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1 α transcriptional activation in pancreatic cancer. *Molecular cell*, 86(14), 2794.

Shaheen MT, et al. (2026) The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. *Cancer research communications*, 6(1), 245.

Zhang S, et al. (2026) Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. *Cell reports. Medicine*, 7(3), 102660.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(13), 3194.

Trekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. *Nature cell biology*, 28(1), 197.

Drouillard D, et al. (2026) Mutant KRAS promotes NF- κ B driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for biology*.

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. *Cell reports. Medicine*, 7(2), 102613.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Zhou X, et al. (2026) DPP4 suppresses pancreatic cancer growth by enhancing ferroptosis sensitivity through stabilization of ACSL4. *Cellular signalling*, 143, 112446.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. *npj biological physics and mechanics*, 2(1), 19.

Liu J, et al. (2025) The role of formin-like protein 1 in pancreatic cancer and its specific effects on immunity. *The Journal of international medical research*, 53(8), 3000605251365844.

Zhan T, et al. (2025) ILF3 mediates lipid metabolism to promote pancreatic cancer development by regulating CPT1A-activated PPAR α signaling pathway. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(7), 167919.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.